GotoPER - Physicians' Education Resource

Optimizing Immune Checkpoint Inhibitors in Early-Stage Cancer Treatment Through Multidisciplinary Collaboration

07/20/2022

July 20, 2022 | 6:30 pm - 8:00 pm ET

Overview

The use of immune checkpoint inhibitors (ICIs) has been well established in metastatic disease, leading to their investigation for use in earlier stages of cancer. Currently, few ICIs are approved for neoadjuvant and adjuvant indications, though clinical trials are underway in melanoma, non−small cell lung cancer, renal cell carcinoma, and other malignancies. In this multidisciplinary panel discussion, experts will review efficacy and safety data supporting the role of ICIs in early-stage cancers and strategies to overcome challenges associated with their therapeutic uptake. The panelists will explore patient populations likely to benefit from early initiation of ICIs in therapy, considerations for initiation and duration of therapy, as well as criteria to determine benefit for patients. The pharmacist’s role and considerations for management of immune-related adverse effects for patients receiving ICIs in the adjuvant setting compared with the metastatic setting will also be discussed.

Target Audience

This educational program is directed toward oncology pharmacists, nurses, and physicians.


Learning Objectives

Upon completion of this activity, participants will be able to:

  • Explore the current and emerging uses of immune checkpoint inhibitors (ICIs) in early stages of cancer and supportive clinical data
  • Compare challenges in integrating ICIs into early-stage cancers among oncologists, oncology nurses, and oncology pharmacists
  • Explain the importance of prompt immune-related adverse effect (irAE) identification in early-stage cancers
  • Develop a plan to monitor and manage irAEs that incorporates collaboration among oncologists, nurses, and pharmacists on the multidisciplinary cancer care team
See all upcoming events